10-Q: Q2 2024 Earnings Report

SECAug 13 16:18 ET · Announcements

Adial Pharmaceuticals Signs Agreement With Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

GlobeNewswireAug 13 09:00 ET

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswireAug 7 09:00 ET

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

GlobeNewswireJul 31 08:30 ET

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswireJul 23 08:30 ET

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

GlobeNewswireJun 20 08:30 ET